NASDAQ:ANAB

AnaptysBio Q1 2025 Earnings Results & Report

AnaptysBio logo
$45.73 -0.52 (-1.12%)
Closing price 04:00 PM Eastern
Extended Trading
$47.28 +1.55 (+3.38%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AnaptysBio beat analyst expectations on both earnings and revenue in its Q1 2025 results, released May 5, 2025. The company reported EPS of -$1.28 versus the -$1.30 consensus estimate, while revenue of $27.77 million topped the $15.27 million estimate by $12.50 million.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens
Conference Call
12:00 AM ET

AnaptysBio EPS Results

Actual EPS
-$1.28
Consensus EPS
-$1.30
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A
EPS Beat Rate
7 of last 8 quarters

AnaptysBio Revenue Results

Actual Revenue
$27.77 million
Expected Revenue
$15.27 million
Beat/Miss
Beat by +$12.50 million
YoY Revenue Growth
N/A

AnaptysBio Q1 2025 Earnings FAQ

AnaptysBio (NASDAQ:ANAB) reported earnings of -$1.28 per share for Q1 2025, beating the consensus estimate of -$1.30. The report was announced on Monday, May 5, 2025.

AnaptysBio reported revenue of $27.77 million for Q1 2025, against a consensus estimate of $15.27 million.

AnaptysBio Earnings Headlines

Financial legend: “This is bad, really bad...”
Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.tc pixel
AnaptysBio, Inc. (ANAB) - What Are Analysts Thinking About This Stock?
See More AnaptysBio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like AnaptysBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AnaptysBio and other key companies, straight to your email.

About AnaptysBio

AnaptysBio (NASDAQ:ANAB) is a biotechnology company focused on developing antibody-based treatments for inflammatory and autoimmune diseases. Its research programs target immune pathways that may be involved in conditions with significant unmet medical needs.

The company’s pipeline has included rosnilimab, an investigational antibody designed to activate the PD-1 pathway, and ANB032, an investigational antibody targeting BTLA. AnaptysBio has also developed imsidolimab, an antibody targeting the IL-36 receptor; global rights to that program were licensed to Vanda Pharmaceuticals.

Founded in 2005 and based in San Diego, California, AnaptysBio also has a history of licensing antibody-discovery programs to other pharmaceutical companies. Its work includes collaborations that have contributed to medicines developed and commercialized by partners.

View AnaptysBio Profile